

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

AUSTAR

奥星

Austar Lifesciences Limited

奥星生命科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6118)

**DISCLOSEABLE TRANSACTION -
TERMINATION OF THE RELOCATION COMPENSATION
AGREEMENT**

Reference is made to the announcement of the Company dated 6 May 2020 (“**Announcement**”) in relation to the Relocation Compensation Agreement. Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as those used in the Announcement.

The Board wishes to announce that, after the entering into of the Relocation Compensation Agreement, as a result of the changing circumstances, on 10 December 2024, Shanghai Austar and Urban Industrial Park Management Committee entered into a termination agreement pursuant to which the Relocation Compensation Agreement was terminated, and all rights and obligations of the Urban Industrial Park Management Committee and Shanghai Austar under the Relocation Compensation Agreement ceased with immediate effect. The Group had not received any payment of the relocation compensation contemplated under the Relocation Compensation Agreement.

The Board is of the view that the termination of the Relocation Compensation Agreement does not have a material adverse effect on the existing business or financial position of the Group.

In accordance with the Group's goal of expanding its capabilities, the Group's facilities on the Songjiang Land and Facility have already been relocated to the Group's new manufacturing center, which is located in Songjiang area of Shanghai. The Group formally commenced operations at this new Shanghai manufacturing center in the first half of 2023.

On behalf of the Board
Austar Lifesciences Limited
Ho Kwok Keung, Mars
Chairman and Chief Executive Officer

Hong Kong, 10 December 2024

As at the date of this announcement, the Board comprises four executive Directors, namely Mr. Ho Kwok Keung, Mars, Mr. Ho Kin Hung, Mr. Chen Yuewu and Madam Zhou Ning; one non-executive Director, namely Madam Ji Lingling; and three independent non-executive Directors, namely Mr. Cheung Lap Kei, Madam Chiu Hoi Shan and Mr. Leung Oi Kin.